

PRIOR AUTHORIZATION CRITERIA

BRAND NAME
(generic)

STROMEKTOL
(ivermectin)

Status: CVS Caremark Criteria

Type: Initial Prior Authorization with Quantity Limit

POLICY

FDA-APPROVED INDICATIONS

Stromectol is indicated for the treatment of the following infections:

- Strongyloidiasis of the intestinal tract. Stromectol is indicated for the treatment of intestinal (i.e., non-disseminated) strongyloidiasis due to the nematode parasite *Strongyloides stercoralis*.
- Onchocerciasis. Stromectol is indicated for the treatment of onchocerciasis due to the nematode parasite *Onchocerca volvulus*.

Stromectol has no activity against adult *Onchocerca volvulus* parasites. The adult parasites reside in subcutaneous nodules which are infrequently palpable. Surgical excision of these nodules (nodulectomy) may be considered in the management of patients with onchocerciasis, since this procedure will eliminate the microfilariae-producing adult parasites.

COVERAGE CRITERIA

The requested drug will be covered with prior authorization when the following criteria are met:

- The requested drug is NOT being prescribed for the prevention or treatment of coronavirus disease 2019 (COVID-19)

Quantity Limits apply.
9 tablets/90 days

REFERENCES

1. Stromectol [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; February 2018.
2. Lexicomp Online, AHFS DI (Adult and Pediatric) Online, Hudson, Ohio: UpToDate, Inc.; 2021; Accessed August 24, 2021.
3. Micromedex (electronic version). IBM Watson Health, Greenwood Village, Colorado, USA. Available at: <https://www.micromedexsolutions.com>. Accessed August 24, 2021.
4. Why You Should Not Use Ivermectin to Treat or Prevent COVID-19. U.S. Food and Drug Administration. Available at: <https://www.fda.gov/consumers/consumer-updates/why-you-should-not-use-ivermectin-treat-or-prevent-covid-19>. Accessed August 24, 2021.
5. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at: <https://www.covid19treatmentguidelines.nih.gov/>. Accessed August 24, 2021.
6. Therapeutics and COVID-19: living guideline – World Health Organization (WHO). Available at: <https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2021.2>. Accessed August 26, 2021.
7. Fryar CD, Carroll MD, Gu Q, Afful J, Ogden CL. Anthropometric reference data for children and adults: United States, 2015–2018. National Center for Health Statistics. Vital Health Stat 3(46). 2021.
8. Merck & Co., Inc. Merck Statement on Ivermectin use During the COVID-19 Pandemic. Available at: <https://www.merck.com/news/merck-statement-on-ivermectin-use-during-the-covid-19-pandemic/>. Accessed August 26, 2021.

